Veracyte, Inc. (VCYT) Dividend History

Veracyte, Inc. is a genomic diagnostics company specializing in advanced diagnostics that help to improve the diagnosis and management of thyroid, lung, and other cancers. The firm develops and commercializes genomic tests that provide more accurate and less invasive alternatives to traditional diagnostic procedures, aiming to reduce unnecessary surgeries and improve patient outcomes. Founded in 2008, Veracyte operates through a platform that combines genomic data with clinical information to assist physicians in making informed treatment decisions.

6000 Shoreline Court, Suite 300, South San Francisco, CA, 94080
Phone: (650) 243-6300

Dividend History

Veracyte, Inc. currently does not pay dividends

Company News

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide

The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

GlobeNewswire Inc.

Featured Companies: ADPT AMGN BIO BIO.B BMY DGX EXAS GH GILD ILMN LH MDXH MYGN NEO NTRA OPK TECH
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Veracyte is considering selling or shutting down its French subsidiary, which generates $4 million in revenue but incurs $7 million in fixed costs, leading to a $5 million loss. An analyst believes this could be a long-term positive for the company.

Benzinga
Should You Continue to Retain PODD Stock in Your Portfolio Now?

Insulet's Omnipod 5 has received FDA approval for type 2 diabetes patients, expanding its market potential. However, economic uncertainty and competitive pressures remain concerns for the company.

Benzinga

Featured Companies: BSX PODD
Globus Medical (GMED) Global Sales, Innovation Aid Growth - Zacks Investment Research

Globus Medical is gaining market share in the musculoskeletal solutions space, driven by strong performance of its products. However, the company is facing challenges from global economic factors, including rising costs and inflation.

Zacks Investment Research

Featured Companies: GMED HAE HIMS
Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT) By GuruFocus - Investing.com Canada

Jens Holstein, a director at Veracyte Inc, sold 5,000 shares of the company's stock. The transaction suggests a neutral sentiment, as insider sales can be driven by various factors, including personal financial needs, rather than a negative outlook on the company's prospects.

Investing.com

Dividend data last updated 06/06/2025 21:43:18 UTC

Veracyte, Inc. (VCYT) Dividend History

Dividend History

Company News

Related Companies